Most pharma teams have years of MLR-approved material sitting in shared drives. Old decks. Old leaflets. Old web pages. Each one containing sentences that were validated by medical, legal, and regulatory reviewers. And each one effectively invisible the next time someone opens a new brief.
So the cycle restarts. New draft. New sources. New review. Three rounds. Forty-seven comments. Veeva has documented the pattern from the reviewer side: as content volume climbs, MLR teams are increasingly cast as the bottleneck, mostly because they are brought in late and forced to re-review material that has barely changed from the last cycle.
The fix is not more reviewers or a faster tool. It is a different starting point. A pharma claims repository, built as an actual system, changes what a reviewer sees on day one.
A pharma claims repository is a modular content library where every approved statement is stored as a standalone, tagged component. Each claim carries its reference, its target audience, its approval status, and its expiry date. It is searchable, reusable, and auditable.
Think of it as the difference between a warehouse full of unlabelled boxes and a warehouse with a real inventory system. The material is the same. The ability to find, reuse, and account for it is completely different.
A repository typically holds:
Promedia's guidance to clients is blunt on this point: approved content is an asset, and a modular content system lets you reuse validated claims and building blocks instead of starting from zero every single time. Treat it like an asset, or keep paying to re-approve it.
Building one is less a technology project than a content-operations discipline. The tooling matters less than the tagging.
Start with a claims audit. Pull three to five recent approved assets per brand and extract every substantive statement. Tag each with its reference, the audience it was approved for, the market, the approval date, and the reference expiry. This gives you a working corpus in weeks, not quarters.
Next, establish a source-visibility standard. Promedia's internal principle here is that MLR reviewers spend disproportionate time tracking down where a statement came from and whether it is still valid. Pre-marking sources inside the document, before submission, saves everyone time. The MLR cycle is not the bottleneck. Everything that happens before submission is.
Finally, decide who owns the repository. Medical affairs, regulatory, or a dedicated content-operations lead. Without a single owner, tags drift, expiries lapse, and the system decays into another shared drive.
Once the repository exists, review cycles compress for a simple reason: the reviewer's job changes. Instead of validating an entire asset from scratch, they are validating what actually changed.
A new brochure gets assembled from approved components. The reviewer sees which claims are reused verbatim, which have been adapted, and which are net-new. Reused claims need a reference recheck and an updated access date. New claims get full scrutiny. The review shrinks to the delta.
This matches what Vodori and others have documented across the industry: AI can automate repetitive pre-checks, identify claims, link them to approved references, and flag gaps before content ever reaches a reviewer. McKinsey has cited pharma companies reducing regulatory submission timelines by 50 to 65 percent through AI-enabled automation of exactly this kind of work.
A pharma-specialist agency treats the MLR process as a quality checkpoint and builds the work around it. The result is fewer review rounds, fewer compliance flags, faster approval, and lower cost. Getting it right the first time is not just better work. It is a better business decision.
This is where AI belongs in pharma content. Not writing new claims. Assembling approved ones.
With a tagged repository as the substrate, compliant content assembly with AI becomes a workflow rather than a risk. The model draws from a closed set of validated components, and every output is traceable to its source claims. Tools like Shaman and others in the MLR automation space already detect changes in claims, references, and image text, focusing reviewers on what has actually changed.
Automated pre-clearance can then check for missing safety language, unsupported claims, outdated references, and formatting issues before content reaches reviewers. That frees MLR teams to focus on scientific accuracy, legal risk, and regulatory judgment, which is what they are actually trained for. Promedia's AI Brand Compliance Checker sits in this same category: automating brand and design-system checks on every asset before it ships, so human reviewers spend their time on the questions only humans can answer.
The repository does something else, quietly, that pays for the whole system: it surfaces what is about to expire.
A reference from 2022 gets flagged before it ends up in a live campaign. A statistic that has been superseded by a newer publication gets replaced before it prints. In pharma, even updating content that seems minor, like a copyright year, may require reapproval of the whole asset. Catching an expired reference before publication costs a review cycle. Catching it after publication costs a recall.
Good repositories run expiry checks automatically and route flagged claims to the right owner. Better ones tie expiry to a content-portfolio view, so teams can see which live assets are affected by a single expiring reference and plan the rework in one batch instead of ten emergencies.
A pharma claims repository is a structured library of MLR-approved statements, stored as modular components with tags for reference, audience, status, and expiry. It replaces the shared-drive model where approved content is effectively invisible after publication, and it acts as the source of truth for any new asset being drafted or assembled.
By extracting approved statements from existing assets, tagging them, and making them searchable, teams can assemble new materials from validated building blocks. Reused claims still need a reference recheck and an updated last access date, but they do not need to be re-argued from scratch. This is the core of modular content in pharma.
AI belongs on the pre-submission side of the workflow. It can identify claims in a draft, link them to approved references, flag missing safety language, detect changes against previously approved versions, and check brand and design-system compliance. It should not be writing new medical claims. It should be assembling and pre-checking approved ones.
Tag every claim with its reference expiry date at the point of approval, then run automated checks that flag claims approaching expiry and identify every live asset affected. This prevents the most expensive kind of rework, which is content pulled or corrected after publication, and it lets teams plan reference updates as a scheduled activity rather than an emergency.
If your team is still drafting every claim from a blank page, the first move is not buying a platform. It is running a claims audit on your three most-used assets and building a tagged inventory from what already exists. That single exercise usually reveals how much approved content is being ignored and how much rework is avoidable.
From there, the repository grows in step with each new campaign, and the review cycle starts to shorten in ways the finance team notices.
If you are mapping this out for a brand or a portfolio, Promedia works with pharma teams on exactly this kind of content-operations infrastructure. Happy to compare notes.
One short email when we publish. No spam, no sales pitch. Unsubscribe whenever.
